Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Meetu Singh Sonsati
Introduction:
Repetitive Transcranial Magnetic Stimulation (rTMS) is becoming an increasingly popular treatment for individuals suffering with severe clinical depression. rTMS uses a magnetic field to alter the electrical signals within the brain. The evidence suggests that individuals with depression show a decreased activity within the dorsolateral prefrontal cortex (DLPFC). High frequency stimulation of this region has shown to significantly reduce depressive symptoms whilst having the benefit of a non-invasive and generally side effect free treatment. We have conducted an internal audit of rTMS patients experiencing depressive symptoms; collating the overall effect of the treatment.
Conclusion:
Analysis of data included 4 time points which did not meet statistical parametric assumptions. This warranted the use of using Spearman’s rho for looking at correlations between week 1 and week 4. The correlation between week 1 and week 4 was found to be statistically significant. In addition, there was a significant effect found for reductions in BDI scores.
The effects of rTMS displayed significant reductions (>50%) in BDI scores attributed to a decrease in depressive symptoms. The research identified the majority of participants transitioned from severe clinical to mild depressive symptoms. rTMS was found to be most effective in adults aged 20-30, however contrary to previous research, rTMS showed strong efficacy for older age adults. There were no significant relationships found between rTMS with ethnic background, number of previous treatments, or clinical depressive classification; with the treatment being equally effective for both genders.